Shares in CSL slid for a second day on Tuesday after the blood products giant said it had “dampened our near-term growth aspirations” for the Vifor iron deficiency and kidney disease therapies business purchased for $US11.7 billion in 2022.

The shares slid 3 per cent to $281.06 by mid-afternoon as news of Vifor’s downgraded outlook overshadowed an 11 per cent increase in underlying first-half net profit to $US2.017 billion ($3.11 billion), a similar increase in the interim dividend and confirmation of double-digit earnings growth for the medium term.